Company
Headquarters: Malvern, PA, United States
Employees: 108
CEO: Mr. Antony Koblish
$108.5 Million
USD as of July 1, 2024
Company | Market Cap (USD) |
---|---|
Abbott | $178.02 B |
Stryker Corporation | $126.48 B |
Boston Scientific Corporation | $112.32 B |
Medtronic | $98.95 B |
Edwards Lifesciences Corporation | $55.63 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
TELA Bio, Inc. has the following listings and related stock indices.
Stock: NASDAQ: TELA wb_incandescent